AR107550A1 - Un trifluoroacetato de agonista de tlr7, la forma cristalina b, proceso de preparación y su utilización - Google Patents

Un trifluoroacetato de agonista de tlr7, la forma cristalina b, proceso de preparación y su utilización

Info

Publication number
AR107550A1
AR107550A1 ARP170100299A ARP170100299A AR107550A1 AR 107550 A1 AR107550 A1 AR 107550A1 AR P170100299 A ARP170100299 A AR P170100299A AR P170100299 A ARP170100299 A AR P170100299A AR 107550 A1 AR107550 A1 AR 107550A1
Authority
AR
Argentina
Prior art keywords
preparation process
trifluoroacetate
tlr7 agonist
crystal form
tlr7
Prior art date
Application number
ARP170100299A
Other languages
English (en)
Spanish (es)
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of AR107550A1 publication Critical patent/AR107550A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
ARP170100299A 2016-02-05 2017-02-06 Un trifluoroacetato de agonista de tlr7, la forma cristalina b, proceso de preparación y su utilización AR107550A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610081899.3A CN107043377A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途

Publications (1)

Publication Number Publication Date
AR107550A1 true AR107550A1 (es) 2018-05-09

Family

ID=59500539

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100299A AR107550A1 (es) 2016-02-05 2017-02-06 Un trifluoroacetato de agonista de tlr7, la forma cristalina b, proceso de preparación y su utilización

Country Status (23)

Country Link
US (1) US10683296B2 (enExample)
EP (1) EP3412674B1 (enExample)
JP (1) JP6877450B2 (enExample)
KR (1) KR102393281B1 (enExample)
CN (2) CN107043377A (enExample)
AR (1) AR107550A1 (enExample)
AU (1) AU2017214135B2 (enExample)
CA (1) CA3013521C (enExample)
CL (1) CL2018002101A1 (enExample)
DK (1) DK3412674T3 (enExample)
EA (1) EA037048B1 (enExample)
ES (1) ES2834304T3 (enExample)
HU (1) HUE052210T2 (enExample)
IL (1) IL260981B (enExample)
MX (1) MX374300B (enExample)
MY (1) MY198137A (enExample)
NZ (1) NZ745023A (enExample)
PH (1) PH12018501641B1 (enExample)
SG (1) SG11201806688QA (enExample)
TW (1) TWI778952B (enExample)
UA (1) UA121276C2 (enExample)
WO (1) WO2017133687A1 (enExample)
ZA (1) ZA201805240B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
AU2017213628B2 (en) 2016-02-05 2021-07-29 Denali Therapeutics Inc. Inhibitors of receptor-interacting protein kinase 1
US12128047B2 (en) 2018-05-25 2024-10-29 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TLR7 agonist and pharmaceutical combination thereof for treating lung cancer
MX2021009496A (es) 2019-02-08 2021-09-08 Progeneer Inc Complejo de colesterol-agonista del receptor 7 u 8 tipo larga distancia, y uso del mismo.
JP2023516372A (ja) 2020-03-02 2023-04-19 プロジェニア インコーポレイテッド 病原菌外壁成分基盤の生病原体模倣ナノ粒子及びその製造方法
JP2023536954A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 活性化部位が一時的に不活性化したトール様受容体7または8作用薬と機能性薬物の結合体およびその用途
JP7690222B2 (ja) 2020-08-04 2025-06-10 プロジェニア インコーポレイテッド 動力学的制御が可能なアジュバントを含むmRNAワクチン
EP4194008A4 (en) 2020-08-04 2025-01-08 Progeneer Inc. Kinetically acting adjuvant ensemble
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
CN119431359A (zh) * 2023-07-28 2025-02-14 苏州申拓医药科技有限公司 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
EA026557B1 (ru) 2008-12-09 2017-04-28 Джилид Сайэнс, Инк. Промежуточные соединения для получения модуляторов толл-подобных рецепторов
CA2826295C (en) 2011-02-04 2020-10-20 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
WO2013103967A1 (en) 2012-01-05 2013-07-11 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
KR102280595B1 (ko) * 2012-10-10 2021-07-22 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 다른 질환 치료를 위한 피롤로[3,2-d]피리미딘 유도체
CA2890201A1 (en) * 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
CN106459058B (zh) * 2014-05-01 2019-07-05 诺华股份有限公司 作为toll-样受体7激动剂的化合物和组合物
KR102139847B1 (ko) * 2014-05-01 2020-07-31 노파르티스 아게 톨-유사 수용체 7 효능제로서의 화합물 및 조성물
CN110759916B (zh) * 2014-08-15 2021-02-19 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN105732635A (zh) * 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂

Also Published As

Publication number Publication date
EA201891772A1 (ru) 2019-01-31
JP6877450B2 (ja) 2021-05-26
ZA201805240B (en) 2024-09-25
PH12018501641B1 (en) 2021-03-26
WO2017133687A1 (zh) 2017-08-10
KR20180104118A (ko) 2018-09-19
US20190031666A1 (en) 2019-01-31
UA121276C2 (uk) 2020-04-27
CN108602833B (zh) 2020-07-28
ES2834304T3 (es) 2021-06-17
MY198137A (en) 2023-08-07
CN107043377A (zh) 2017-08-15
MX374300B (es) 2025-03-06
TWI778952B (zh) 2022-10-01
TW201728591A (zh) 2017-08-16
NZ745023A (en) 2022-09-30
AU2017214135B2 (en) 2020-08-13
HK1259182A1 (zh) 2019-11-29
CA3013521A1 (en) 2017-08-10
EP3412674B1 (en) 2020-09-16
CA3013521C (en) 2022-07-12
EP3412674A1 (en) 2018-12-12
IL260981B (en) 2022-05-01
EP3412674A4 (en) 2019-07-17
MX2018009503A (es) 2018-12-11
CN108602833A (zh) 2018-09-28
PH12018501641A1 (en) 2019-06-03
EA037048B1 (ru) 2021-01-29
JP2019504103A (ja) 2019-02-14
HUE052210T2 (hu) 2021-04-28
BR112018015878A2 (pt) 2018-12-26
DK3412674T3 (da) 2020-11-09
KR102393281B1 (ko) 2022-05-02
AU2017214135A1 (en) 2018-08-23
SG11201806688QA (en) 2018-09-27
CL2018002101A1 (es) 2018-12-07
US10683296B2 (en) 2020-06-16

Similar Documents

Publication Publication Date Title
AR107550A1 (es) Un trifluoroacetato de agonista de tlr7, la forma cristalina b, proceso de preparación y su utilización
EA201891768A1 (ru) Кристаллическая форма a агониста tlr7, ее способ получения и использование
CO7170131A2 (es) Compuestos de heterociclilo
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
MX2019009100A (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
BR112015005404A2 (pt) Formas polimórficas de enzalutamida e sua preparação
ECSP18010481A (es) Composiciones de plinabulina
UY36226A (es) Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
MX2015014081A (es) Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor de canabinoides 2 (cb2).
CL2018002094A1 (es) Un proceso para preparar compuesto de pirrolo[3,2–d]pirimidina y su intermediario
CO2017000443A2 (es) Derivados de 3h, 4h, 6h, 7h-piran[3,4-d]imidazol-4-ona activos como inhibidores de la aldosterona sintasa
CL2017001100A1 (es) Nuevas triazolo[4,5-d]pirimidinas
MX382724B (es) Formas sólidas de ceftolozano.
UY35610A (es) Derivados de prodroga de triazolpiridinas sustituidas
AR101951A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
RU2014118884A (ru) Средство для снижения алкогольной мотивации при алкогольной зависимости
CO2017002070A2 (es) Un proceso para la preparación de derivados de 3-fenil/heteroaril-6-fenoxi-8-alquilamino-imidazo[1,2-b] piridazina
UY35347A (es) Formas cristalinas de un inhibidor de la prolil hidroxilasa
MX2017006679A (es) Formas cristalinas de inhibidores de poli adp-ribosa polimerasa (parp).

Legal Events

Date Code Title Description
FC Refusal